MediFront

Medifront is a South Korean biotechnology company specializing in the development of therapeutics and diagnostics for neurodegenerative diseases and chronic pain. The company's primary focus is on Alzheimer's disease, where it has developed a blood-based diagnostic kit and is advancing small molecule candidates designed to inhibit amyloid-beta aggregation. Additionally, Medifront is developing TRPV1 antagonists for the treatment of neuropathic pain. Listed on the KOSDAQ, the company leverages its proprietary technology to address significant unmet needs in the central nervous system (CNS) space. Its lead therapeutic candidate, MDR-1339, has undergone clinical evaluation for its potential to modify the progression of Alzheimer's disease.